Menopause and hormone therapy in Panama: what the FDA changed

The FDA shift: from boxed warning to individual judgment

In Panama, menopause typically occurs between ages 45 and 48, according to gynecologist Yerina Lee of the Caja de Seguro Social (CSS) Dr. Blas Gómez Chetro polyclinic in Arraiján, quoted by Panamá América in a 2021 piece edited in May 2025⁷. Meanwhile, the US Food and Drug Administration (FDA) changed the regulatory picture for hormone therapies that many Panamanian physicians prescribe or consult.

On November 10, 2025, the FDA announced it was starting to remove the boxed warning from menopausal hormone therapy products: the references to cardiovascular disease, breast cancer and probable dementia. The endometrial cancer warning on systemic estrogen-alone products stays². On February 12, 2026 it approved the first label changes for six products, and 29 companies had submitted proposals at the agency's request¹³⁴.

The agency recommends broader framing: starting systemic therapy for moderate to severe vasomotor symptoms in women younger than 60 or within 10 years of menopause onset⁵. In the February release, the FDA cites randomized studies in which women who start within that window have lower all-cause mortality and fewer fractures¹. The sources we read differ on the details of which warnings remain on each product, so check each drug's current label³⁵.

What the evidence says: WHI, timing and breast cancer

The starting point was the WHI estrogen plus progestin trial, stopped in 2002. It found hazard ratios of 1.29 for coronary heart disease, 1.26 for invasive breast cancer and 1.41 for stroke, with an absolute excess of 8 invasive breast cancers per 10,000 person-years and 5 fewer hip fractures⁹. The FDA then added the boxed warning, and according to press coverage, use fell from about 22% to about 4%³.

Later analyses nuance that picture. The integrated WHI summary with extended follow-up found that, with estrogen alone, women aged 50 to 59 had more favorable results for all-cause mortality, myocardial infarction and the global index, and that most risks and benefits dissipated after stopping treatment¹⁰. In ELITE, oral estradiol slowed carotid intima-media thickness progression when started less than 6 years after menopause but not at 10 years or more; there was no effect on coronary calcium by CT¹³.

The less comfortable part for the shift is breast cancer. In the 20-plus-year WHI follow-up, conjugated equine estrogen alone was associated with lower breast cancer incidence (HR 0.78) and lower breast cancer mortality (HR 0.60), but estrogen plus medroxyprogesterone acetate was associated with higher incidence (HR 1.28) and no significant difference in mortality¹¹. An individual-participant meta-analysis by the Collaborative Group on Hormonal Factors in Breast Cancer, with 108,647 cases, found excess risk with every type of therapy except vaginal estrogens, rising with duration and greater with estrogen-progestagen (RR 2.08 in years 5 to 14 of current use) than with estrogen alone (RR 1.33)¹².

On the brain, the KEEPS trial randomized recently menopausal women to 4 years of oral conjugated equine estrogen (0.45 mg/day) or transdermal estradiol (50 µg/day), both with micronized progesterone, versus placebo; its cognitive and affective analysis was published in 2015¹⁴. A 2026 report with 10-year follow-up found no adverse effects or benefits on amyloid or MRI biomarkers¹⁵. Meanwhile, the US Preventive Services Task Force (USPSTF) keeps its 2022 grade D recommendation against hormone therapy for primary prevention of chronic conditions; it does not assess symptom treatment¹⁶.

The local gap: where is the Panamanian guideline

We looked for a Panamanian clinical guideline on menopause and hormone therapy from the Ministry of Health (Minsa), the CSS or the Sociedad Panameña de Ginecología y Obstetricia, and did not find one online. That does not prove no internal protocol exists; it means a physician cannot cite one from public sources. What we did find is the Panamá América piece: according to Dr. Lee, the CSS offers hormone therapy after consultation, with cytology, mammography and transvaginal ultrasound, plus counseling, exercise and calcium and collagen supplements⁷.

There are also signals from patients. In May 2026, La Estrella de Panamá reported on two founders of «El Club de las Peri», who say many women go through perimenopause without information and ask the health system to keep up with recent guidelines; the report gives no statistics or specific guidelines⁸. For the wider regulatory context, see our peptides in Panama guide and the analysis of longevity clinics in Panama.

Where peptides fit (and where they don't)

The FDA decision concerns approved hormonal products (estrogens, progestogens and combinations), not peptides. None of the sources cited in this article describes kisspeptin or growth hormone secretagogues as a menopause treatment, and the use of those molecules remains in the research setting. For the underlying biology, see our notes on kisspeptin and growth hormone secretagogues.

What did advance, and shares vocabulary with peptide neuroendocrinology, are nonhormonal drugs aimed at neurokinin B signaling. A phase 2 trial of an oral NK3 receptor antagonist (MLE4901) reduced hot flushes by 45 percentage points versus placebo, with three cases of raised transaminases¹⁷. In the phase 3 SKYLIGHT 1 trial, fezolinetant reduced vasomotor symptom frequency versus placebo at week 12, with infrequent liver enzyme elevations¹⁸. On October 24, 2025 the FDA approved elinzanetant, a dual NK1 and NK3 receptor antagonist, for moderate to severe hot flashes¹⁹. These are regulated oral molecules, not injectable peptides, and their existence supports no research product.

The marketing caution is practical: broader label language from the FDA does not turn a research product into a menopause option. Public Citizen argued that the FDA appeared to promote off-label uses of hormone therapy, such as cardiovascular and cognitive protection⁶. If that complaint applies to approved drugs, it applies even more to «hormonal longevity» messaging built on molecules with no indication.